ArticleSensors (Basel, Switzerland)2026
NeuroSPFNet: Vision-Language Semantic Prior-Guided Frequency-Enhanced Network for Brain Tumor Segmentation in Multimodal MRI.
Article in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Accurate brain tumor segmentation in multimodal magnetic resonance imaging (MRI) scans is essential for quantitative neuro-oncology analysis, treatment planning, and longitudinal disease monitoring. However, automatic delineation remains challenging because glioma subregions exhibit heterogeneous appearance across T1-weighted (T1), contrast-enhanced T1-weighted (T1ce), T2-weighted (T2), and fluid-attenuated inversion recovery (FLAIR) sequences; weak and irregular lesion boundaries; and severe scale variation between edema, tumor core, and enhancing tumor regions. This paper presents NeuroSPFNet, a vision-language semantic prior-guided frequency-enhanced segmentation framework for tumor subregion delineation in multimodal MRI volumes. NeuroSPFNet integrates four complementary components: a Clinical Vision-Language Prior Component (CVLPC) for category-level semantic guidance; a Frequency-Enhanced Boundary Module (FEBM) for boundary-sensitive representation learning; a Multi-Scale Lesion-Dominated Fusion Module (MLDFM) for hierarchical lesion aggregation; and a Lesion-Semantic Boundary Consistency Loss (LSBCL) for jointly constraining region overlap, boundary quality, and semantic alignment. The task-specific contribution lies in the closed coupling of shared BraTS-region semantic prototypes, gated frequency responses, lesion-weighted multiscale features, and semantic-boundary supervision within one volumetric segmentation pipeline. On the Brain Tumor Segmentation (BraTS) 2021 benchmark, NeuroSPFNet achieved Dice scores of 91.94%, 88.84%, and 85.38% for whole tumor, tumor core, and enhancing tumor, respectively, with a mean Dice of 88.72% and a mean 95th-percentile Hausdorff distance (HD95) of 3.58 mm. Ablation studies show distinct effects across subregions and metrics: semantic priors primarily strengthen tumor-core and enhancing-tumor discrimination, whereas frequency and boundary constraints primarily reduce contour error. NeuroSPFNet also attains competitive performance under the current setting, with moderate computational overhead of 42.58 million parameters, 78.60 billion floating-point operations (GFLOPs), and 265 ms per volume.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.